# United States SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

### **SCHEDULE 13G**

**Under the Securities Exchange Act of 1934** 

# VOYAGER THERAPEUTICS, INC.

(Name of Issuer)

Common Stock (Title of Class of Securities)

> 92915B106 (CUSIP Number)

January 3, 2018 (Date of Event Which Requires Filing This Statement)

<del></del>
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
⊠ Rule 13d-1(c)
☐ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

#### CUSIP No. 92915B106

1.	Names o	of Reportin	g Persons
		otech AG	
2.			iate Box if a Member of a Group (See Instructions)
	(a) ⊠	(b) 🗆	
3.	SEC Use	Only	
4.	Citizens	hip or Plac	e of Organization
	Switze		
		5.	Sole Voting Power
			0
	mber of Shares	6.	Shared Voting Power
	neficially wned by		1,786,341
	Each	7.	Sole Dispositive Power
	eporting son with:		0
		8.	Shared Dispositive Power
			1,786,341
9.	Aggrega	te Amount	Beneficially Owned by Each Reporting Person
	1,786,3		
10.	Check if	the Aggre	gate Amount in Row (9) Excludes Certain Shares
11.	Percent (	of Class Re	epresented by amount in Row (9)
	5.6%		
12.	Type of	Reporting	Person (See Instructions)
	нс,сс	)	

# CUSIP No. 92915B106 Names of Reporting Persons Biotech Target N.V. I.R.S. Identification Nos. of above persons (entities only): N/A Check the Appropriate Box if a Member of a Group (See Instructions) (a) 🗵 3. SEC Use Only Citizenship or Place of Organization Curacao 5. Sole Voting Power Number of Shared Voting Power Shares Beneficially 1,786,341 Owned by 7. Sole Dispositive Power Each Reporting Person with: 8. Shared Dispositive Power

1,786,341

#### 1,786,341

- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares □
- 11. Percent of Class Represented by amount in Row (9)

## 5.6%

12. Type of Reporting Person (See Instructions)

 $\mathbf{CO}$ 

	1(a)	Name	of Issuer: <u>Voyager Therapeutics, Inc.</u>
	1(b)	Addre	ess of Issuer's Principal Executive Offices:
		<u>75 Sid</u>	ney Street, Cambridge, Massachusetts 02139
<b>T</b> .			
Item		<b>N</b> T	
			of Person Filing: BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Target N.V. ("Biotech Target")
	2(b)		ss of Principal Business Office or, if none, Residence:
			otech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland
		Biotec	h Target N.V.: Snipweg 26, Curacao
	2(c)	Citizei	nship: BB Biotech AG: Switzerland
			Biotech Target N.V.: Curacao
	2(d)	Title o	f Class of Securities <u>Common Stock, \$0.001 par value</u>
	2(e)	CUSII	P Number <u>92915B106</u>
Item	2		
		omont is	s filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
II UII			
			roker or Dealer registered under Section 15 of the Act.
			ank as defined in Section 3(a)(6) of the Act.
			surance company as defined in Section 3(a)(19) of the Act.
			vestment company registered under section 8 of the Investment Company Act of 1940.
			n investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
		_	n employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
	J		parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
			savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	i.		church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment ompany Act of 1940;
	j.	□ Gı	roup, in accordance with Rule 13d-1(b)(1)(ii)(J).
			4 of 7

Item 1

P	Provi	de the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(ä	a)	Amount beneficially owned: <u>1,786,341</u>
(l	b)	Percent of class:5.6%
(0	c)	Number of shares as to which the person has:
(i	i)	Sole power to vote or to direct the vote0
(i	ii)	Shared power to vote or to direct the vote <u>1,786,341</u>
(i	iii)	Sole power to dispose or to direct the disposition of0
(i	iv)	Shared power to dispose or to direct the disposition of <u>1,786,341</u>
		nership of Five Percent or Less of a Class s statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more
		ercent of the class of securities, check the following: $\Box$
Item 6.	. Ow	nership of More than Five Percent on Behalf of Another Person.  N/A
Item 7. Contro		ntification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or eson.
<u>I</u>	his :	statement is filed jointly by BB Biotech and Biotech Target, Biotech Target is a wholly-owned subsidiary of BB Biotech.
Item 8.	Ide	ntification and Classification of Members of the Group  N/A
Item 9.	Not	ice of Dissolution of Group
		5 of 7

Item 4. Ownership

#### **Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURES**

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG			
Date: <u>January 8, 2018</u>	By:	/s/ Michael Hutter	
		Signatory Authority	
	Name:	Michael Hutter	
	Title:	Signatory Authority	
Date: <u>January 8, 2018</u>	Ву:	/s/ Ivo Betschart	
		Signatory Authority	
	Name:	Ivo Betschart	
	Title:	Signatory Authority	
Biotech Target N.V.			
Date: January 8, 2018	By:	/s/ Michael Hutter	
		Signatory Authority	
	Name:	Michael Hutter	
	Title:	Signatory Authority	
Date: <u>January 8, 2018</u>	Ву:	/s/ Ivo Betschart	
		Signatory Authority	
	Name:	Ivo Betschart	
	Title:	Signatory Authority	

6 of 7

### Exhibit A

### **Joint Filing Statement**

We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

# BB Biotech AG

Date:	<u>January 8, 2018</u>	By:	/s/ Michael Hutter	
			Signatory Authority	
		Name:	Michael Hutter	
		Title:	Signatory Authority	
Date:	<u>January 8, 2018</u>	Ву:	/s/ Ivo Betschart Signatory Authority	
			Signatory Authority	
		Name:	Ivo Betschart	
		Title:	Signatory Authority	
		Biotech T	Target N.V.	
Date:	<u>January 8, 2018</u>	Ву:	/s/ Michael Hutter	
Date:	<u>January 8, 2018</u>	Ву:	/s/ Michael Hutter Signatory Authority	
Date:	<u>January 8, 2018</u>	By:		
Date:	<u>January 8, 2018</u>		Signatory Authority	
	<u>January 8, 2018</u> <u>January 8, 2018</u>	Name:	Signatory Authority  Michael Hutter  Signatory Authority  /s/ Ivo Betschart	
		Name:	Signatory Authority  Michael Hutter  Signatory Authority	
		Name:	Signatory Authority  Michael Hutter  Signatory Authority  /s/ Ivo Betschart	
		Name: Title:	Signatory Authority  Michael Hutter  Signatory Authority  /s/ Ivo Betschart  Signatory Authority	